Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PulmoSIM Therapeutics Granted Orphan Drug Designation for PT001
Details : The preclinical results of PT001 in this indication have been very encouraging. The development of this new therapy will directly improve the standard of care for PAH patients by reducing morbidity and enhancing the quality of life at a reasonable cost.
Brand Name : PT001
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 15, 2021
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?